Dapagliflozin and Hydrochlorothiazide in Recurring Kidney Stone Patients

Launched by MEDICAL UNIVERSITY OF VIENNA · Jun 29, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called Dapagliflozin to see if it can help prevent kidney stones in people who are at high risk of having them again. Kidney stones can be quite painful, and current treatments don’t always work well in preventing future stones from forming. Dapagliflozin is already known to help some patients with diabetes, and researchers want to find out if it can also lower the amount of oxalate—a substance that can lead to kidney stones—being released in the urine compared to another medication called Hydrochlorothiazide.

To participate in this trial, you need to be between the ages of 65 and 74 and have a history of calcium-oxalate kidney stones, meaning you've had at least two stones that caused symptoms or needed surgery in the last decade. You may also qualify if you have certain family history or health conditions related to kidney stones. The trial is not yet recruiting participants, but if you join in the future, you can expect regular check-ups and tests to monitor your health and how well the medication is working. This study could provide new options for preventing kidney stones in people who are most at risk.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Calcium-oxalate stone formers with high risk of reoccurrence defined as:
• • At least two symptomatic or surgically treated kidney stones within the last 10 years and/or
• • Single stone kidney formers with risk factors including: a.) Positive medical family history on kidney stone formations of at least one blood related relative in the first degree or at least two blood related relatives in the second degree and/ or b.) Onset of kidney stone formations within the third life decade or earlier and/ or c.) Metabolic syndrome d.) Obesity (BMI ≥ 30 kg/m²)
• Exclusion Criteria:
• • Age \< 18 years
• • Malabsorption disorder
• • eGFR \< 30 ml/min/1,73 m2